AR049138A1 - Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis - Google Patents
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesisInfo
- Publication number
- AR049138A1 AR049138A1 ARP050102263A ARP050102263A AR049138A1 AR 049138 A1 AR049138 A1 AR 049138A1 AR P050102263 A ARP050102263 A AR P050102263A AR P050102263 A ARP050102263 A AR P050102263A AR 049138 A1 AR049138 A1 AR 049138A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- optionally substituted
- substituted
- group
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 17
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical class 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- -1 hydroxy, methoxy Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas que contienen tales compuestos y al uso de esos compuestos y composiciones para la prevencion y/o tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis. Reivindicacion 1: Un compuesto de formula (1) en la cual R1 se selecciona del grupo integrado por arilo, bencilo, y heteroarilo, donde arilo y heteroarilo pueden estar opcionalmente sustituidos con 0, 1, 2, 3 o 4 sustituyentes seleccionados independientemente del grupo integrado por alquilo C1-4, donde alquilo C1-4 puede estar sustituido con 0, 1, 2 o 3 halogenos, 0 o 1 heterociclilo, o 0 o 1 alcoxi C1-3, donde alcoxi C1-3 puede estar opcionalmente sustituido con alquilamino C1-3, alcoxi C1-3, donde alcoxi C1-3 puede estar opcionalmente sustituido con alquilamino C1-3, halogeno, trifluorometilo, trifluorometoxi, cicloalquilo C3-6, fenilo opcionalmente sustituido con 1 o 2 halogenos, un resto de formula (2), donde X es CH2, O, S o NR1-1, y donde R1-1 es H o alquilo C1-6, nitro, ciano, alquiltio C1-3, trifluorometiltio, alquil C1-3-carbonilo, alcoxi C1-6-carbonilo, y fenoxi, donde fenoxi puede estar opcionalmente sustituido con 0, 1 o 2 sustituyentes seleccionados independientemente del grupo integrado por alquilo C1-6, alcoxi C1-6, trifluorometoxi y halogeno, y donde bencilo puede estar sustituido con 0, 1, 2 o 3 grupos seleccionados de halogeno, alquilo C1-3 y alcoxi c1-3; R2 se selecciona del grupo integrado por H, halogeno, alquilo C1-4 y alcoxi C1-4; R3 se selecciona del grupo integrado por carboxilo, formilo, alquil C1-6-carbonilo opcionalmente sustituido con 0, 1, 2 o 3 grupos seleccionados de F, Cl, hidroxi, alcoxi C1-6, y heterociclo, cicloalquil C3-6-carbonilo, alcoxi C1-6-carbonilo opcionalmente sustituido con 0, 1, 2 o 3 grupos seleccionados de amino y alcoxi C1-6-carbonilo, aminocarbonilo, alquilamino C1-6-carbonilo, donde alquilamino C1-6-carbonilo puede estar opcionalmente sustituido con 0, 1, 2 o 3 sustituyentes seleccionados independientemente del grupo integrado por cicloalquilo C3-6, halogeno, amino, alquilamino C1-6, hidroxi, alcoxi C1-6, alcoxi C1-6-carbonilo, alquiltio C1-6, alcoxi C1-6- carbonilamino, y metilsulfonilo, y donde alquilamino C1-6-carbonilo puede estar opcionalmente sustituido con o 0 o 1 heterociclilo, donde heterociclilo puede estar opcionalmente sustituido con 0 o 1 alquilo C1-6, y donde alquilamino C1-6-carbonilo puede estar opcionalmente sustituido con 0 o 1 fenilo, donde fenilo puede estar opcionalmente sustituido con 0 o 1 halogeno, alquilo C1-6, o alcoxi C1-6; heterociclilcarbonilo opcionalmente sustituido con 0 o 1 amino, alquilamino C1-6, cicloalquilo, o alquilo C1-6, donde alquilo C1-6 puede estar opcionalmente sustituido con 0 o 1 amino o alquilamino C1-6; alquilo C1-6 opcionalmente sustituido con 0, 1, 2 o 3 sustituyentes seleccionados independientemente del grupo integrado por: a) hidroxilo, b) amino, c) alquilamino C1-6, donde alquilamino C1-6 puede estar sustituido con 0, 1, 2, 3 o 4 sustituyentes seleccionados independientemente del grupo integrado por halogeno, amino, alquilamino, metoxi, metilito y metilsulfonilo, d) arilamino, donde arilamino puede estar sustituido con 0, 1 o 2 sustituyentes seleccionados independientemente del grupo integrado por alquilo C1-6, alcoxi C1-6, y trifluorometilo, e) heterociclilo, donde heterociclilo puede estar sustituido con 0, 1 o 2 alquilo C1-6, donde alquilo C1-6 puede estar sustituido con 0, 1 o 2 hidroxi, metoxi o piridilo; f) imidazolilo, g) piridilamino, h) alcoxi C1-3 opcionalmente sustituido con fluoro hasta el nivel de perfluoro, o con heterociclo, donde heterociclo puede estar opcionalmente sustituido con 0 o 1 alquilo C1-6, i) alcoxi C1-3-alcoxi C2-3, y j) alcoxi C1-6-carbonilo, k) cicloalquilo C3-6, l) ciano, alcoxi C1-6 opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados independientemente del grupo integrado por amino, alquilamino C1-6, y heterociclilo, donde heterociclilo puede estar sustituido con 0, 1, 2 o 3 alquilo C1-6, cicloalquilamino C3-6-carbonilo opcionalmente sustituido con alquilo C1-3, ciano, heteroarilo, donde heteroarilo puede estar sustituido con 0, 1, 2 o 3 grupos seleccionados independientemente del grupo integrado por k) alquilo C1-6, donde alquilo C1-6 puede estar sustituido con 0, 1, 2 o 3 halogeno, 0 o 1 heterociclilo, 0 o 1 alquilamino, o 0 o 1 hidroxi o metoxi, l) halogeno, m) amino, n) alquilamino, o) alcoxi C1-6-carbonilo, y p) cicloalquilo C3-6, heteroarilcarbonilo, el cual puede estar sustituido con 0, 1, 2 o 3 grupos seleccionados independientemente del grupo integrado por alquilo C1-6, cicloalquilo C3-6 y halogeno, heterociclilo, donde heterociclilo puede estar sustituido con 0, 1, 2, o 3 grupos seleccionados independientemente del grupo integrado por alquilo C1-6 y alcoxi C1-6-carbonilo; y R4 se selecciona del grupo integrado por H, alquilo C1-6, alcoxi C1-6 y halogeno; o su sal aceptable para uso farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57665204P | 2004-06-03 | 2004-06-03 | |
| US62653104P | 2004-11-09 | 2004-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049138A1 true AR049138A1 (es) | 2006-06-28 |
Family
ID=34971944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102263A AR049138A1 (es) | 2004-06-03 | 2005-06-02 | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7563791B2 (es) |
| EP (1) | EP1765823B1 (es) |
| JP (1) | JP4958772B2 (es) |
| KR (1) | KR101235602B1 (es) |
| CN (1) | CN1993361B (es) |
| AR (1) | AR049138A1 (es) |
| AT (1) | ATE462708T1 (es) |
| AU (1) | AU2005252217B2 (es) |
| BR (1) | BRPI0510848A (es) |
| CA (1) | CA2569396C (es) |
| DE (1) | DE602005020293D1 (es) |
| EC (1) | ECSP067043A (es) |
| ES (1) | ES2342722T3 (es) |
| GT (1) | GT200500137A (es) |
| HN (1) | HN2005000255A (es) |
| IL (1) | IL179264A0 (es) |
| MA (1) | MA28689B1 (es) |
| MX (1) | MX279139B (es) |
| MY (1) | MY145077A (es) |
| NO (1) | NO20070049L (es) |
| NZ (1) | NZ551742A (es) |
| PE (1) | PE20060243A1 (es) |
| PH (1) | PH12006502386B1 (es) |
| RU (1) | RU2401269C2 (es) |
| SG (1) | SG127661A1 (es) |
| SV (1) | SV2006002134A (es) |
| TW (1) | TW200608979A (es) |
| UY (1) | UY28931A1 (es) |
| WO (1) | WO2005121147A1 (es) |
| ZA (1) | ZA200700011B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CA2631741C (en) | 2005-12-02 | 2014-01-28 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| WO2007071752A2 (en) | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| EP1882475A1 (en) * | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
| US7912582B1 (en) * | 2007-05-03 | 2011-03-22 | Innovation Associates, Inc. | Robotic prescription filling system |
| KR101553211B1 (ko) | 2007-09-10 | 2015-09-15 | 씨아이피엘에이 엘티디. | Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체 |
| MX2010003269A (es) * | 2007-09-25 | 2010-08-02 | Bayer Healthcare Llc | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. |
| EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
| AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
| WO2012177782A1 (en) * | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| SG195100A1 (en) | 2011-07-01 | 2013-12-30 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| JP6047582B2 (ja) * | 2011-12-15 | 2016-12-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用 |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| WO2013124316A1 (en) | 2012-02-23 | 2013-08-29 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| EP3157920B1 (en) | 2014-06-17 | 2019-08-07 | Chiesi Farmaceutici S.p.A. | Indolizine derivatives as phosphoinositide 3-kinases inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CA3016161A1 (en) | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| HUE064656T2 (hu) | 2016-03-28 | 2024-04-28 | Incyte Corp | Pirrolotriazin vegyületek mint TAM inhibitorok |
| WO2018161033A1 (en) * | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| KR102739325B1 (ko) | 2017-09-27 | 2024-12-09 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| ES3031110T3 (en) | 2018-06-29 | 2025-07-04 | Incyte Corp | Formulations of an axl/mer inhibitor |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| WO2020142557A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| SG11202111327XA (en) * | 2019-05-13 | 2021-11-29 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| CN114621233A (zh) * | 2019-09-26 | 2022-06-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的芳香稠合环衍生物及其组合物及用途 |
| AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
| US12534479B2 (en) * | 2020-07-10 | 2026-01-27 | Findcure Biosciences (Zhongshan) Co., Ltd. | Triazine compound and composition and use thereof |
| TW202233625A (zh) | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| EP4384179A1 (en) | 2021-08-11 | 2024-06-19 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| CN119816500A (zh) | 2021-08-20 | 2025-04-11 | 拜欧米富士恩公司 | 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式 |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2097384C1 (ru) * | 1989-10-31 | 1997-11-27 | Биокрист Фармасьютикалз Инк. | Производные 2-амино-7-(chr2r3)-3н,5н-пирроло[3,2-d]-пиримидин-4-она, способы их получения и способ селективного ингибирования пролиферации т-лимфоцитов млекопитающего и не оказывающий воздействия на b-лимфоциты |
| AU770377B2 (en) * | 1999-05-21 | 2004-02-19 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| HRP20030485A2 (en) * | 2000-11-17 | 2004-08-31 | Bristol Myers Squibb Co | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| EP1543009A4 (en) * | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US7405213B2 (en) | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CA2631741C (en) * | 2005-12-02 | 2014-01-28 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| MX2010003269A (es) * | 2007-09-25 | 2010-08-02 | Bayer Healthcare Llc | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. |
-
2005
- 2005-05-30 UY UY28931A patent/UY28931A1/es not_active Application Discontinuation
- 2005-06-01 MY MYPI20052508A patent/MY145077A/en unknown
- 2005-06-01 HN HN2005000255A patent/HN2005000255A/es unknown
- 2005-06-02 GT GT200500137A patent/GT200500137A/es unknown
- 2005-06-02 TW TW094118090A patent/TW200608979A/zh unknown
- 2005-06-02 AR ARP050102263A patent/AR049138A1/es not_active Application Discontinuation
- 2005-06-02 PE PE2005000618A patent/PE20060243A1/es not_active Application Discontinuation
- 2005-06-03 AU AU2005252217A patent/AU2005252217B2/en not_active Ceased
- 2005-06-03 NZ NZ551742A patent/NZ551742A/en unknown
- 2005-06-03 RU RU2006147237/04A patent/RU2401269C2/ru not_active IP Right Cessation
- 2005-06-03 CA CA2569396A patent/CA2569396C/en not_active Expired - Lifetime
- 2005-06-03 US US11/596,913 patent/US7563791B2/en not_active Expired - Lifetime
- 2005-06-03 BR BRPI0510848-9A patent/BRPI0510848A/pt not_active IP Right Cessation
- 2005-06-03 CN CN2005800260347A patent/CN1993361B/zh not_active Expired - Fee Related
- 2005-06-03 EP EP05758135A patent/EP1765823B1/en not_active Expired - Lifetime
- 2005-06-03 KR KR1020077000040A patent/KR101235602B1/ko not_active Expired - Fee Related
- 2005-06-03 JP JP2007515588A patent/JP4958772B2/ja not_active Expired - Fee Related
- 2005-06-03 AT AT05758135T patent/ATE462708T1/de not_active IP Right Cessation
- 2005-06-03 MX MXPA06013457 patent/MX279139B/es active IP Right Grant
- 2005-06-03 SV SV2005002134A patent/SV2006002134A/es unknown
- 2005-06-03 DE DE602005020293T patent/DE602005020293D1/de not_active Expired - Lifetime
- 2005-06-03 ES ES05758135T patent/ES2342722T3/es not_active Expired - Lifetime
- 2005-06-03 SG SG200608387A patent/SG127661A1/en unknown
- 2005-06-03 WO PCT/US2005/019472 patent/WO2005121147A1/en not_active Ceased
-
2006
- 2006-11-14 IL IL179264A patent/IL179264A0/en unknown
- 2006-11-28 PH PH12006502386A patent/PH12006502386B1/en unknown
- 2006-11-30 EC EC2006007043A patent/ECSP067043A/es unknown
- 2006-12-28 MA MA29573A patent/MA28689B1/fr unknown
-
2007
- 2007-01-02 ZA ZA2007/00011A patent/ZA200700011B/en unknown
- 2007-01-03 NO NO20070049A patent/NO20070049L/no not_active Application Discontinuation
-
2009
- 2009-07-20 US US12/506,033 patent/US8338595B2/en not_active Expired - Fee Related
-
2012
- 2012-12-20 US US13/722,793 patent/US20130225809A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049138A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| AR049139A1 (es) | Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii. | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| ATE517885T1 (de) | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs | |
| EA033294B1 (ru) | Пиридазиноновые гербициды | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| MY150588A (en) | Herbicidal pyridazinone derivatives | |
| AR053567A1 (es) | Derivados de pirazoliloxifenilo sustituidos, composiciones herbicidas que los contienen y un procedimiento para combatir plantas no deseadas que los comprende. | |
| EA200801996A1 (ru) | 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR081821A1 (es) | Antranilamidas sustituidas con triazol como plaguicidas | |
| PE20241934A1 (es) | Inhibidores de raf quinasa y metodos de uso de los mismos | |
| CO6460742A2 (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica | |
| AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
| PE20070795A1 (es) | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa | |
| WO2008088727A3 (en) | Endothelin receptor antagonists | |
| EP2602254A4 (en) | HETEROCYCLIC CONNECTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |